Screener
ClearPoint Neuro CLPT Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by ClearPoint Neuro in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221890
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from stock option exercises | 148 | 21 |
| Payments for taxes related to net share settlement of equity awards | (1,993) | (1,305) |
| Net cash flows from financing activities | (1,845) | (1,362) |
| Net change in cash, cash equivalents and restricted cash | (10,457) | (7,717) |
| Cash, cash equivalents and restricted cash, beginning of period | 46,973 | 20,104 |
| Cash, cash equivalents and restricted cash, end of period | $36,516 | $12,387 |
| Cash and cash equivalents | 35,593 | 12,387 |
| Restricted cash included in other current assets and other assets, non-current | 923 | — |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is ClearPoint Neuro's net change in cash?
- ClearPoint Neuro (CLPT) reported net change in cash of -$10.46M in Q1 2026.
- How has ClearPoint Neuro's net change in cash changed year-over-year?
- ClearPoint Neuro's net change in cash decreased by 35.5% year-over-year, from -$7.72M to -$10.46M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about ClearPoint Neuro's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude